37 results about "Metabolic derangement" patented technology

Compounds of formula I which act as amylin agonists with respect to certain desired amylin activities and as calcitonin agonists with respect to certain desired calcitonin activities are provided. Such compounds are useful in treating disturbances in fuel metabolism in mammals, including, but not limited to diabetes mellitus, including Type I diabetes and Type II diabetes. The present invention also relates to methods of treating Type I diabetes, treating Type II diabetes and to methods of beneficially regulating gastrointestinal motility comprising administration of a therapeutically effective among of one of the compounds. Also provided are pharmaceutical composition comprising a compound of formula I and a pharmaceutically acceptable carrier.

The invention relates to a method for investigating the glucose metabolism of a human being for disease-relevant and / or disease-related particularities. The the glucose concentration g(t1) to g(tn) of a body fluid is measured at time points t1 to tn that are distributed over a period of at least six hours. The data points are then determined in phase space coordinates from the glucose concentration measuring values g(t1) to g(tn). The data points are then processed to highlight disease-relevant and / or disease-related particularities of the glucose metabolism of the investigated human being. The processing of the data points can be implemented by plotting them in a phase space representation or by determining from the data points a disturbance parameter that is correlated to the severity of a disturbance of glucose metabolism.

The invention provides a new application of berberine in the treatment of metabolic syndrome. Large-sample polycentric and randomized double-blind prospective experiments reveal the effect of berberine on metabolism of glucose and lipid and clarify the interrelation and common changes of the metabolism of glucose and lipid before and after berberine treatment. The berberine is used as a broad spectrum antibiotic and clinical drug with high efficiency and low toxicity for a long time and can be taken chronically without obvious side effect. Results of researches indicate that the berberine can help sufferers of type II diabetes mellitus combined with blood lipid abnormality regulate disorder of saccharometabolism and lipid metabolism, lower insulin resistance, avoid central obesity and elevation of blood pressure, thereby showing the positive effect of the berberine on the treatment of metabolic syndrome. The invention provides the new clinical application of berberine in the treatment of metabolic syndrome for human for the first time, which establishes the importance of the new clinical application of traditional Chinese medicine in the treatment of metabolic syndrome and provides a new basis as well, thereby helping to promote the traditional medicine of China.

Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.

The invention provides a medicine structurally containing a liver-targeting specific ligand and a thyroxine receptor agonist. The liver-targeting specific ligand and the thyroxine receptor agonist areconnected by branched chains, connectors and connecting chains to form a novel medicine structure. Thyroxine receptors (TRs) are divided into two subtypes, namely TR-alpha and TR-beta, wherein the TR-beta is mainly expressed in the liver, and the TR-alpha is mainly expressed in the heart, the nervous system and the like. In some embodiments, the medicine provided by the invention is expected to have a liver-targeting effect and can specifically bring the thyroxine receptor agonist into the liver so as to prevent the thyroxine receptor agonist from entering the heart and other tissues, so thatside effects triggered by the effect of the thyroxine receptor agonist on the other tissues can be avoided and the therapeutic effect of the medicine on treatment of lipid metabolism disorders and related complications is maintained.

Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.

Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows am efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.

The invention provides a hypolipidemic compound 9-demethylberberine. The 9-demethylberberine is derived from a main in-vivo metabolite of natural medicine berberine, and is also named as berberrubine. The researches on model animals with hyperlipidemia find that the 9-demethylberberine has good drug effects of reducing cholesterol, triglyceride, low density lipoprotein (LDL) and the like, and has no obvious side effects for 6 weeks of continuous medication. The discovery can lead to discovery of a new hypolipidemic drug, and provides another alternative medicine for clinic treatment of hyperlipidemia, lipid metabolism disorder and high fat and obese patients and related people wanting to lose weight.

Methods and compositions for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods and compositions can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia and for preventing or reducing weight gain due to factors such as drug use, cessation of smoking, and the like in a human subject.

Compounds which inhibit certain activities of amylin but which also act as amylin agonists with respect to other amylin activities are disclosed. Such compounds are useful in treating disturbances in fuel metabolism in mammals, including but not limited to, diabetes, mellitus, including Type I diabetes and Type II diabetes, impaired glucose tolerance, insulin resistance and Syndrome X. The present invention also relates to methods of treating Type I diabetes, beneficially regulating gastrointestinal motility, treating impaired glucose tolerance, treating postprandial hyperglycemia, treating obesity and treating Syndromne X, comprising administration of a therapeutically effective amount of certain compounds, as described herein.

The invention provides, inter alia, methods of monitoring the fructose response of a subject by determining the level of fibroblast growth factor 21 (FGF21) gene expression product in a biological sample (such as a serum sample) from the subject, where the subject was previously administered a fructose bolus. The invention also provides methods of monitoring the response of a subject to a treatment for a disorder of metabolism, for discriminating fructose intolerance from other gastrointestinal disorders not associated with fructose intolerance, for identifying a subject at risk for developing a disorder of metabolism, as well as methods of treatment for a disorder of metabolism.

The invention provides a hypolipidemic compound demethyleneberberine. The demethyleneberberine is derived from a main in-vivo metabolite of natural medicine berberine. The researches on model animals with hyperlipidemia find that the demethyleneberberine has good drug effects of reducing cholesterol, triglyceride, low density lipoprotein (LDL) and the like, and has no obvious side effects for 6 weeks of continuous medication. The discovery can lead to discovery of a new hypolipidemic drug, and provides another alternative medicine for clinic treatment of hyperlipidemia, lipid metabolism disorder and high fat and obese patients and related people wanting to lose weight.

The invention discloses a composite enteral nutrition applicable to AIDS patients. The composite enteral nutrition comprises nutrients such as proteins, fat, carbohydrates, vitamins, minerals and dietary fibers required by human bodies. The nutrition has a good clinical nutritional supporting effect on the AIDS patients, is beneficial to absorption of the AIDS patients and improvement of poor nutrient conditions of the patients compared with a common whole protein type nutrition, and can obviously improve the living quality of the patients; compared with a common nutrient group, the nutrition has the advantages of remarkably improving the nutrient conditions of the patients and lightening the decline of various physical measurement indexes such as weight caused by AIDS; various biochemical indexes of blood of the patients can be remarkably improved, the blood sugar and the blood fat of the patients are adjusted, and the insulin resistance and the lipid metabolism disorder of the patients are lightened; and the intestinal floras of the patients are adjusted, the intestinal barrier function of the patients is protected, diarrhea caused by the flora disorder of the patients is reduced, the immunity of the patients is enhanced, and the opportunistic infections caused by intestinal flora translocation are reduced.

The invention provides a Chinese traditional medicine compound preparation for decreasing blood-lipid and improving blood rheology. Root of red rooted slbia, root of common peony, angelica, Hirude nipponica Whitman, radix curcumae, vinegar corydalis tuber, raw fleece-flower root, fruit of hawthorn, oriental water plantain rhizome, milkvetch root, gastrodia elata, villous amomum fruit, alcohol cyperus tuber, prepared Liauorice Root, root of thomson kudzuvine and medicinal cyathula root are crushed, sieved, and then added with medical active carbon and distilled water, and the mold is drawn, and the product is roughly prepared, covered, dried, polished, sterilized by the radiation of cobalt 60 and packaged in bottles. The medicine of the invention can significantly decrease blood-lipid and improve blood rheology. The invention fully demonstrates the lipid-regulating effect of the medicines in the prescription by either coordinating or adding the medicines, medical, not only the blood-lipid is regulated and but the blood rheology is greatly improved. The invention also has good effect on regulating lipid metabolism disorder of the rat of hyperlipidemia and improving hemorheology and has good prevention effect on hyperlipemia, atherosclerosis and relevant cardio-cerebrovascular diseases.

The present invention relates to a Chinese medicine prescription preparation with the functions of clearing away heat, moistening illness caused by pathogenic dryness, nourishing yin, promoting production of body fluid, tonifying spleen and kidney, promoting blood circulation and removing blood stasis for effectively curing diabetes and its complication fat metabolic disturbance with obvious therapeutic effect. Said Chinese medicine prescription preparation is made up by using 5 Chinese medicinal materials of lycium root bark, coptis root, epimedium, pueraria root and turmeric through a certain preparation process.

The invention discloses steroid saponin compounds and a preparation method and application thereof. The preparation method comprises the steps of: mixing polygonatum odoratum with an aqueous solutionof ethanol for extraction, performing filtration and concentration by using an ultra filtration membrane and nanofiltration membrane device, then performing adsorption by using a macroporous resin column, performing elution with an aqueous solution of ethanol, performing concentration and recycling of ethanol, and performing freeze drying or spray drying to obtain steroid saponin extract; separating the steroid saponin extract by using low-and-medium pressure liquid chromatography with an OSD column, performing gradient elution by using a methanol aqueous solution with a volume concentration of 10-100%, and performing purification by using a preparative RP-HPLC to obtain the eight steroid saponin compounds. The steroid saponin compounds can be applied to prepare drugs for treating, improving and / or preventing metabolic syndromes, metabolic diseases, metabolic disorder and liver cancers of sugar or fat, food functional additives or healthy food, and the preparation method has simple operation and is easy to industrialize and popularize.

The invention provides application of a ring finger protein Rnf20 gene. By using a Cre-loxp system, an adipose tissue specific Rnf20 gene knockout mouse model is successfully prepared through mating of an Rnf20Flox / Flox mouse and an Adiponectin-Cre + mouse. Adipose specific Rnf20 gene knockout mice (Rnf20Fox / Fox; Adipectin-Cre +) and the control mice (Rnf20Flox / Flox) were used as experimental subjects to study the function of the Rnf20 gene in fat metabolism through animal models induced by age and high fat diet. The results show that compared with thecontrol mice, the adipose-specific Rnf20 gene knockout mice has lipid metabolism disorders that could mimic the pathogenesis of human lipodystrophy. The model is an ideal model for researching lipodystrophy, and has important application value.

A low-dosage injection of tanshinone IIA-sodium sulfonate for treating coronary heart disease, angina pectoris, myocardial infarction and ventricular premature contraction is prepared from the tanshinone IIA-sodium sulfonate through depositing in water, cold storage, ultrafiltration, adding additives in dark condition, pouring in containers in Na atmosphere, sterilizing and lamp examining.

The invention belongs to the technical field of medicine, and relates to a purpose of angelicin to preparation of medicine for treating hyperlipemia. Pharmacology tests show that the angelicin has a good treatment effect on a hyperlipemia rat model for the first time. The treatment effect of the angelicin on a hyperlipemia dyslipidemia rat model built for high-fat feed feeding is systemically studied; the result shows that the angelicin has an obvious treatment effect on the hyperlipemia rat model; the TC (total cholesterol), the TG (triglyceride) and the LDL-C (low density lipoprotein cholesterin) of a hyperlipemia rat are reduced; the HDL-C (high density lipoprotein cholesterin) is increased; meanwhile, the effect of simultaneously reducing the cholesterol and the triglyceride of the hyperlipemia rat is achieved.

The present invention discloses a balloon catheter capable of controlling blocking amount of blood flow. The balloon catheter capable of controlling blocking amount of blood flow comprises a balloon catheter body and a guide wire, the balloon catheter body is composed of a catheter body, a balloon and a Y-shaped catheter base, a front end of the guide wire is provided with a head end and a springring, the catheter body is composed of a flexible far-end section, a balloon section and a rigid pushing shaft section, a first guide wire cavity is formed in the flexible far-end section, a developing mark ring is further arranged at one end, close to the rigid pushing shaft section, of the balloon section, and a balloon channel and a guide wire channel are formed in the Y-shaped catheter base. The balloon catheter capable of controlling blocking amount of blood flow can adapt to a long operation time, can properly open a vascular access, control blood flow, avoid ischemia or metabolic disorders of downstream organs and improve a survival rate of patients in an operation of blocking an aneurysm or a blood vessel for a long time. Besides, due to a multi-cavity structure, the guide wire cavity and the balloon cavity are independent of one another, positions of the catheter and the guide wire can be flexibly adjusted during a balloon-filling period, operation of an operator is facilitated, and operation time is shortened.

The present invention discloses a use of bergenin in preparation of drugs for treatment of diabetes, and belongs to the field of the pharmacological use of the bergenin. The results of animal experiments show that: with the bergenin, the model forming rate of type 2 diabetes rats can be significantly reduced, the occurrence and the development of insulin resistance can be prevented, the insulin resistance degree of the rats can be significantly reduced, and the insulin sensitivity of the type 2 diabetes rats can be effectively improved. In addition, the results provided by the present invention further show that: with the bergenin, the triglyceride content and the total cholesterol content in blood serum can be significantly reduced, and the lipid metabolism disorder of the type 2 diabetes rats can be effectively improved. Therefore, the results show that the bergenin can be used for preparing into the drugs for the treatment of the diabetes and the blood lipid reducing drugs.

Methods for regulating food intake in a human subject; for improving a compliance of a human subject to caloric restriction; and for reducing a desire of a human subject to consume fats, utilizing H1-receptor agonists that have a pharmacological half-life that allows an efficient treatment regime thereof are disclosed. The methods can be efficiently used for treating conditions such as overeating, overweight, obesity, binge eating disorder, night eating syndrome, obsessive eating, compulsive eating and bulimia, as well as conditions associated with metabolic derangement such as dyslipidemia.

A seven-carbon fatty acid, preferably n-heptanoic acid, has been identified as an excellent energy source for patients suffering from inherited metabolic disorders or acquired metabolic derangements, especially defects in long-chain fatty acid metabolism. A seven-carbon fatty acid can also be provided in a nutritional supplement for patients who need an increase in the energy production derived from fatty acid metabolism.

The invention discloses steroid saponin compounds and a preparation method and application thereof. The preparation method comprises the steps of: mixing polygonatum odoratum with an aqueous solutionof ethanol for extraction, performing filtration and concentration by using an ultra filtration membrane and nanofiltration membrane device, then performing adsorption by using a macroporous resin column, performing elution with an aqueous solution of ethanol, performing concentration and recycling of ethanol, and performing freeze drying or spray drying to obtain steroid saponin extract; separating the steroid saponin extract by using low-and-medium pressure liquid chromatography with an OSD column, performing gradient elution by using a methanol aqueous solution with a volume concentration of 10-100%, and performing purification by using a preparative RP-HPLC to obtain the eight steroid saponin compounds. The steroid saponin compounds can be applied to prepare drugs for treating, improving and / or preventing metabolic syndromes, metabolic diseases, metabolic disorder and liver cancers of sugar or fat, food functional additives or healthy food, and the preparation method has simple operation and is easy to industrialize and popularize.

The current invention relates to the use of a physiologically acceptable organic and / or inorganic vanadium compound or complex, such as for example bis(maltolato)oxovanadium (BMOV) in the prevention or amelioration of stress-induced metabolic derangement in a subject. More in particular, the invention relates to a physiologically acceptable organic and / or inorganic vanadium compound or complex foruse in the amelioration of hyperglycemia in a subject suffering from stress such as elicited by a trauma, wherein the physiologically acceptable organic and / or inorganic vanadium compound or complexis administered to said subject before the trauma is inflicted to the subject. Furthermore, the invention relates to a physiologically acceptable organic and / or inorganic vanadium compound or complexfor use in the prevention of hyperglycemia in a subject having a trauma, wherein the physiologically acceptable organic and / or inorganic vanadium compound or complex is administered to said subject before the subject has the trauma. In one embodiment a physiologically acceptable organic and / or inorganic vanadium compound or complex is administered to a human subject 2 to 24 hours before said humansubject is subjected to surgery, for the prevention or amelioration of hyperglycemia elicited by a trauma related to the surgery. It is part of the invention that the physiologically acceptable organic and / or inorganic vanadium compound or complex are a source of vanadyl or vanadate in a patient to whom such compound or complex is administered.

The invention discloses a novel purpose of pteris multifida poir general flavone in preparation of medicine for treating hyperlipemia and atherosclerosis. The lipid-lowering and anti-atherosclerosis effects are studied through a rat lipid metabolism disturbance model and an atherosclerosis model; study results prove that the pteris multifida poir general flavone can reduce the contents of TG, CHO and LDL-C in the rat blood serum; the H / L ratio is increased; the atherosclerotic plaque length and area can be reduced; good lipid-lowering and anti-atherosclerosis effects are achieved; the pteris multifida poir general flavone can be prepared into medicine applied to the aspect.

A food product containing high affinity phosphate binders (calcium and magnesium) for the purpose of chelating phosphate forms ingested foods and preventing its absorption. The chelation of phosphate in the intestine is an important part of the management of patients with moderate to severe renal failure including those in the predialysis and the dialysis dependent stages. The medicinal food product is a palatable source of calcium and magnesium which if taken without meals can be used as means to supplement those ions / salts. This concept of “food as medicine” represents a major reinforcement in the prevention and management of the derangements of divalent ion metabolism present at all levels of renal insufficiency. Limiting the gastrointestinal absorption of phosphate and consequently preventing the elevation of plasma phosphate, retards the onset of renal osteodystrophy (a Metabolic Bone Disease) and soft tissue calcification.